Drugs / VVD-130037
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05954312 | Jul 2023 → Aug 2030 expected | cancer | Vividion Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VVD-130037 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05954312 ↗ |
| Action | Activate | “a Kelch-like ECH Associated Protein 1 (KEAP1) Activator” NCT05954312 ↗ |
| Route | Oral | “Participants will receive ascending doses of VVD-130037, orally, once or twice daily in 21-day treatment cycles during Part 1.” NCT05954312 ↗ |
| Target | KEAP1 | “a Kelch-like ECH Associated Protein 1 (KEAP1) Activator” NCT05954312 ↗ |